1
Exhibit (a)(11)

INVERESK COMPLETES TENDER OFFER FOR CLINTRIALS RESEARCH INC., SCOTLAND, April 3,
2001 - Inveresk Research Group Limited announced that Inveresk has completed its
tender offer for the outstanding shares of common stock of ClinTrials Research
Inc. (NASDAQ: CCRO). The tender offer expired at 12:00 midnight, New York City
time, on Monday, April 2, 2001. Based on preliminary information received from
SunTrust Bank, the Depositary for the tender offer, a total of 17,720,100 shares
(including 35,474 shares subject to guaranteed delivery), representing
approximately 96.3% of the outstanding shares of common stock of ClinTrials
Research Inc., were tendered prior to the expiration of the tender offer and not
withdrawn. All shares validly tendered have been accepted for payment in
accordance with the terms of the offer. Under the terms of the merger agreement
among Inveresk Research Group Limited, its indirect, wholly owned subsidiary,
Indigo Acquisition Corp., and ClinTrials Research Inc. which was announced on
February 22, 2001, Inveresk will complete its acquisition of ClinTrials Research
Inc. by effecting a "short form" merger under Delaware law, in which the
remaining ClinTrials Research Inc. shares of common stock will be converted into
the right to receive $6.00 net per share in cash. The merger is expected to be
completed within the next few days.

ClinTrials is a global contract research organization headquartered near
Research Triangle Park, North Carolina with offices in Maidenhead, England;
Glasgow, Scotland; Montreal, Canada; Brussels, Belgium; Paris, France;
Melbourne, Australia; Tel Aviv, Israel; Milan, Italy; Warsaw, Poland; Madrid,
Spain; and Munich, Germany. With more than 1,500 employees, ClinTrials provides
comprehensive research services, including monitoring, data management and
biostatistics, medical and regulatory services to pharmaceutical, biotechnology
and medical device clients.

Headquartered near Edinburgh, Scotland, Inveresk is a leading European provider
of contract research services, primarily to the pharmaceutical and biotechnology
industry.

THIS RELEASE CONTAINS FORWARD-LOOKING STATEMENTS, INCLUDING STATEMENTS ABOUT
FUTURE BUSINESS OPERATIONS, FINANCIAL PERFORMANCE AND MARKET CONDITIONS. SUCH
FORWARD-LOOKING STATEMENTS INVOLVE RISKS AND UNCERTAINTIES INHERENT IN BUSINESS
FORECASTS. THIS RELEASE IS NEITHER AN OFFER TO PURCHASE NOR A SOLICITATION OF AN
OFFER TO SELL SECURITIES OF CLINTRIALS RESEARCH INC. THE TENDER OFFER IS BEING
MADE SOLELY BY AN OFFER TO PURCHASE AND RELATED LETTER OF TRANSMITTAL
DISSEMINATED UPON THE COMMENCEMENT OF THE TENDER OFFER AND AMENDED FROM TIME TO
TIME. SHAREHOLDERS OF CLINTRIALS RESEARCH INC. SHOULD READ THE TENDER OFFER
STATEMENT BECAUSE IT CONTAINS IMPORTANT INFORMATION. THESE DOCUMENTS ARE
AVAILABLE TO CLINTRIALS SHAREHOLDERS AT NO CHARGE AND ARE ALSO AVAILABLE FOR
FREE AT THE SEC'S WEB SITE (HTTP://WWW.SEC.GOV).

CONTACT: GCI Christopher Gordon (212) 886-3428 ClinTrials Research, Inc. Paul
Ottaviano Chief Executive Officer (919) 460-9005